A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension

Exclusion Criteria

• •Has a diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements
• •Has received prior systemic anticancer therapy for metastatic NSCLC
• •Has received prior systemic anticancer therapy including investigational agents within 4 weeks before randomization
• •Has received prior radiotherapy within 2 weeks of start of study intervention or has radiation-related toxicity requiring corticosteroids
• •Has received radiation therapy to the lung (\>30 Gray) within 6 months of start of study intervention
• •Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention
• •Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
• •Has a known additional malignancy that is progressing or has required active treatment within the past 3 years
• •Has an active autoimmune disease that has required systemic treatment in past 2 years
• •Has an active infection requiring systemic therapy
• •Has a history of human immunodeficiency virus (HIV) infection
• •Has a history of Hepatitis B or C
• •Has not adequately recovered from major surgery or has ongoing surgical complications
• •Has a history of allogenic tissue/solid organ transplant